E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
This is a Phase II trial to determine the efficacy of intravenous CNTO 328 in women with the following diseases: recurrent epithelial ovarian cancer, Fallopian tube carcinoma, primary peritoneal carcinoma of serous, endometrioid or clear cell sub-types. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066697 |
E.1.2 | Term | Ovarian cancer recurrent |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine efficacy of intravenous CNTO 328 in women with recurrent epithelial ovarian cancer. |
|
E.2.2 | Secondary objectives of the trial |
a) To determine changes in Quality of Life in patients with recurrent epithelial ovarian cancer following treatment with CNTO328. b) To determine the neutralisation of IL-6 in tumour, blood and ascitic specimens following treatment with CNTO328. c) To determine the alterations in inflammatory markers in blood, ascitic fluid and tumour tissue (where possible) following intravenous delivery of CNTO 328 in recurrent epithelial ovarian cancer and determine whether any of these biomarkers are predictive of response.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Women with recurrent histologically confirmed ovarian carcinoma, Fallopian tube carcinoma, or primary peritoneal carcinoma of serous, endometrioid or clear cell sub-types. • Previous treatment with no more than three platinum-containing chemotherapy regimes. • Patients are also eligible if they have relapsed within six months of completing first line platinum-containing chemotherapy or have experienced documented progression whilst receiving first-line platinum-containing chemotherapy • Life expectancy of at least 3 months • Age ≥ 18 years • WHO performance status of 0, 1 or 2 • Patients must have the following clinical laboratory values: Granulocyte count > 1.0 x 109/l Platelet count > 100 x 109/l Hb > 9.0 g/dl Serum creatinine < 1.5 x Upper Limit of Normal (ULN) Bilirubin < 30 µmol/l Albumin > 30 g/dl Prothrombin and activated partial thromboplastin times < 1.5 x ULN Alk Phos < 5 x ULN
|
|
E.4 | Principal exclusion criteria |
• Tumours of malignant mixed mesodermal (MMMT) or mucinous types. • Unresolved bowel obstruction • Prior administration of or hypersensitivity to humanised monoclonal antibodies • Chemotherapy within the preceding 3 weeks • Radiotherapy within the preceding 3 weeks • Treatment with any investigational agent within the preceding 4 weeks or within 5 half-lives of the investigational agent, whichever is longer. Known leptomeningeal involvement • Pregnant or lactating females. • Inability or unwillingness to give informed consent. • Ongoing active infection or a documented history of HIV infection, Hepatitis B or C. • Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease (Appendix 7). • Concurrent autoimmune disorder, e.g. systemic lupus or any demyelinating disease. • No corticosteroids to be taken within the preceding 4 weeks
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be any response (SD, PR or CR) in any of the patients. All patients will be staged with conventional (CT) imaging prior to treatment, after 5 treatments and every 3 months until end of treatment, to assess disease response to CNTO 328. Measurable disease in the CT component will be assessed by modified RECIST criteria.. CA-125 will also be measured at enrolment, prior to each infusion and at the end treatment. CA-125 responses will also be assessed according to the criteria of the GCIG and correlated to the CT response. Patients will additionally be investigated with [18F]-FDG PET scan imaging. The FDG-PET responses will be assessed according to the criteria of Avril et al. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The entire trial will be stopped when:
• The drug is considered too toxic to continue treatment prior to the required number of patients being recruited • The total number of patients to be recruited (20) is reached.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |